Request an Appointment Online, or call us at (888) 824-0200

The University of Chicago Medicine - Comer Children's Hospital

Pediatric Brain & Spinal Cord Tumor Care

Families of children with brain and spinal cord tumors face great challenges, but finding comprehensive, compassionate care shouldn't be one of them. Our brain and spinal cord tumor program provides families with a wide array of diagnostic, treatment, rehabilitation and support services so that each child has the best chance for a cure, as well as the best possible quality of life.

Brain and spinal cord tumors in children often need to be treated differently than those in adults. That's why it's important to work with physicians who understand the unique challenges that children face and who have access to the most advanced therapies.

A Multidisciplinary Team

Pediatric experts from the following disciplines may also be part of a child's team:

  • Pediatric oncology
  • Pediatric neurosurgery
  • Radiation oncology
  • Pediatric neurology
  • Pediatric endocrinology
  • Ophthalmology
  • Neuroradiology
  • Neuropathology
  • Neuropsychology
  • Genetics
  • Rehabilitation
  • Occupational therapy
  • Physical therapy
  • Audiology
  • Speech therapy
  • Social work
  • Child life

Learn more about our team.

Physicians meet weekly to discuss cases, share viewpoints and weigh the pros and cons of different brain tumor management plans. Every brain tumor case is discussed in this Tumor Board meeting before treatment is determined.

Advancing Research

There have been tremendous advances in brain tumor care in recent years. Our team is committed to furthering research in this area. We work to improve current treatments and identify options for brain and spinal cord tumors that do not respond to conventional therapies.

Comer Children's collaborates with research groups around the country to give patients access to the most promising treatments available in clinical trials. Some of these research groups include the National Cancer Institute, the Children's Oncology Group and the Neurofibromatosis Research Program.